← Back to Search

Other

Perfluorohexyloctane eye drop for Dry Eye Syndrome

N/A
Waitlist Available
Led By Jennifer Fogt, OD MS
Research Sponsored by Ohio State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

The purpose of this study is to explore the tear lipid layer quantitatively and qualitatively before and after use of a perflurohexyloctane eye drop (NovaTears)

Eligible Conditions
  • Dry Eye Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Perfluorohexyloctane eye dropExperimental Treatment1 Intervention
Participants will have their tear lipid layer assessed. They will then have the eye drop instilled and will have an additional assessment of the tear lipid layer within 5 minutes of instillation of the the drop, and again 15 minutes after instillation.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
NovaTears
2022
N/A
~20

Find a Location

Who is running the clinical trial?

Ohio State UniversityLead Sponsor
865 Previous Clinical Trials
655,020 Total Patients Enrolled
Jennifer Fogt, OD MSPrincipal InvestigatorOSU College of Optometry
2 Previous Clinical Trials
55 Total Patients Enrolled
~6 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top